PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Trial aims to improve treatment for newborns with life-threatening sepsis

An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.

Trial aims to improve treatment for newborns with life-threatening sepsis
2023-05-23
(Press-News.org) An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.

The trial, which has started in three public hospitals in South Africa and Kenya, will be expanded to other countries and regions in 2024, with a target of recruiting up to 3,000 newborns overall.

The NeoSep1 trial will evaluate new combinations of generic antibiotics and compare them to existing treatment regimens that are often used in newborn babies with suspected neonatal sepsis.

Chris Hani Baragwanath Academic Hospital in Johannesburg, Tygerberg Hospital in Cape Town and KEMRI, Kilifi County Hospital in Kenya are involved in the initial stage of the clinical trial.

Neonatal sepsis, a life-threatening infection, affects up to 3 million babies a year globally. It has become increasingly challenging as about 40% of infections are reported to be resistant to standard antibiotic treatments. Over 214,000 newborn babies die of drug-resistant neonatal sepsis every year, mostly in low- and middle-income countries (LMICs).  

The trial is sponsored by the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with the Medical Research Council Clinical Trials Unit at UCL (MRC CTU at UCL); St George’s, University of London; and Penta.

“Many babies are dying because of limited treatment options. The NeoSep1 trial is an opportunity to shift this trajectory by identifying new antibiotic combinations that we can tailor to treat neonatal sepsis in settings where there is widespread resistance to current recommended options. This is vital if we are going to address the impact of antimicrobial resistance on the burden of disease related to neonatal sepsis,” said Seamus O’Brien, Director of Research and Development at GARDP.

The trial will rank the safety and efficacy of three new combinations of older antibiotics (fosfomycin-amikacin, flomoxef-amikacin, and flomoxef-fosfomycin) against the current standard of care. It will also assess and validate the doses of two antibiotics (fosfomycin and flomoxef) for use in newborns.

A key goal is to find out whether some antibiotic treatments perform better than others for the empiric treatment of babies with neonatal sepsis, particularly in LMICs where highly resistant bacteria are common. The trial will also consider how these combination treatments can best be used in hospital settings with varying levels of antibiotic resistance.

A new way of comparing antibiotic treatments with each other, called the Personalised Randomised Controlled Trial (PRACTical) design, will be used. The novelty of this design is that it allows researchers to compare many antibiotic treatments for neonatal sepsis. It will also enable doctors to choose treatment regimens that are likely to work well for newborns in their particular hospital settings.

“The development pipeline for new antibiotic treatments is limited and the lack of a universal, effective standard of care creates huge challenges in conducting research to tackle neonatal sepsis. Novel trial designs such as the PRACTical design have been specifically developed to address these challenges in important public health emergencies such as neonatal sepsis,” said Sarah Walker, Professor of Medical Statistics and Epidemiology at the MRC CTU at UCL.

The NeoSep1 trial builds on findings from a global observational study of sepsis in newborn babies, conducted by GARDP and partners in 19 hospitals in 11 countries from 2018 to 2020. GARDP published a report on the study in 2022.

The study found a worryingly wide variation in treatment and frequent switching of antibiotics because of high resistance to treatments.  

“Newborns handle medicines very differently to older infants, children and adolescents. Premature or otherwise critically ill babies are at great risk of severe infection or sepsis because of their immature immune systems.  The types of bacteria causing newborn infections are not necessarily the same as those found in other patients. For these reasons, it is essential to investigate antibiotic treatments of newborns with sepsis,” said Dr Julia Bielicki, paediatrician and researcher in the Centre for Neonatal and Paediatric Infection at St George’s, University of London.

The trial aims to generate relevant and reliable evidence for doctors who need to make treatment decisions, especially in hospitals where there are high levels of antimicrobial resistance.

“We often have to treat babies with a combination of the antibiotics of last resort. On top of this we are not 100% sure about how to dose these drugs. We’re dealing with fragile newborns, so we need to be aware of the potential toxicity of the antibiotics and dosages we use. This trial will help in giving us confidence that we are delivering more effective treatment. This is critical as we want the best possible outcome for newborns in our care,” said Adrie Bekker, Principal Investigator for the NeoSep1 trial at Tygerberg Hospital, Cape Town, and Professor in the Division of Neonatology, Department of Paediatrics and Child Health at Stellenbosch University. 

“We need to treat newborn babies in our care promptly and effectively otherwise there is great risk that babies could die or are left with neurodevelopment impairment. Having the right antibiotics can make the difference between life and death. We are hoping the trial will provide robust evidence that the antibiotic combinations are safe and effective and that this will lead to a change in both WHO and local treatment guidelines,” said Christina Obiero, Principal Investigator for the NeoSep1 trial for the KEMRI-Wellcome Trust Research Programme at Kilifi County Hospital, Kenya.

END


[Attachments] See images for this press release:
Trial aims to improve treatment for newborns with life-threatening sepsis

ELSE PRESS RELEASES FROM THIS DATE:

Previous smallpox vaccine provides immunity to mpox

2023-05-23
Vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox (previously known as monkeypox), researchers from Karolinska Institutet in Sweden report in a study published in the scientific journal Cell Host & Microbe. During last year’s mpox outbreak, the virus spread for the first time outside Africa, causing over 85,000 cases of the disease to date. Men who have sex with men account for the most infections, with a marked skew towards the young. The virus that causes mpox is what is known as an orthopoxvirus and is very similar to the virus that caused ...

Fever found to be most common non-respiratory feature of SARS-CoV-2 infection

Fever found to be most common non-respiratory feature of SARS-CoV-2 infection
2023-05-23
Session:  C58, Health Services Research in Diverse Settings Date and Time: 11:30 a.m. ET, Tuesday, May 23, 2023 Location:  WEWCC, Area 1, Hall C (Lower Level)   ATS 2023, Washington, DC – Fever was found to be the most common non-respiratory feature of infection with SARS-CoV-2, the virus that causes COVID-19, according to research published at the ATS 2023 International Conference.  The finding held true regardless of which COVID variant patients had, and whether or not they were fully vaccinated or not fully vaccinated. The researchers, who also looked at mortality risk, found that patients who were ...

International group of experts redefines concussions

2023-05-23
Doctors and other health-care providers have a new standard for diagnosing mild traumatic brain injury (TBI), thanks to a thorough process led by researchers from the University of B.C. and Harvard-affiliated Spaulding Rehabilitation Hospital. "We've achieved consensus across a diverse range of experts in developing these new diagnostic criteria,” said Dr. Noah Silverberg, associate professor in UBC’s department of psychology, member of the Djavad Mowafaghian Centre for Brain Health and Centre for Aging SMART at Vancouver Coastal Health, and co-lead of the project. “Our ...

USC Health System Board appoints Paul B. Rothman, MD, as board member

USC Health System Board appoints Paul B. Rothman, MD, as board member
2023-05-23
LOS ANGELES — Paul B. Rothman, MD, has been appointed as a member of the USC Health System Board, which provides strategic oversight and governance over Keck Medicine of USC and university clinical services.  Rothman, former CEO of Johns Hopkins Medicine and retired dean of medical faculty for the Johns Hopkins University School of Medicine, brings his leadership acumen as well as clinical and scientific expertise in rheumatology and molecular immunology to this advisory role.  “Paul ...

Diagnosis of type 1 diabetes after SARS-CoV-2 infection: Researchers find possible correlation

2023-05-23
Different studies have documented an increased incidence of type 1 diabetes during the COVID-19 pandemic. However, none of the studies distinguishes between children with and without SARS-CoV-2 infection. Researchers were now able to gain new insights: the KVB data set provides information on whether children diagnosed with type 1 diabetes previously had COVID-19. This allows an analysis of the temporal relationship between a COVID-19 diagnosis and the diagnosis of type 1 diabetes. Amongst the analyzed children without ...

RPI and Albany Medical College researchers awarded $3.3 million to improve breast cancer treatment using artificial intelligence

RPI and Albany Medical College researchers awarded $3.3 million to improve breast cancer treatment using artificial intelligence
2023-05-23
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College were awarded a $3.3 million grant over five years by the National Cancer Institute to use artificial intelligence (AI) to improve targeted drug therapy in HER2-positive breast cancer treatment. HER2-positive breast cancer tends to grow and spread quickly, but targeted treatments improve outcomes. The research is being led by Xavier Intes, Rensselaer professor of biomedical engineering and co-director of the Center for Modeling, Simulation and Imaging in Medicine, and ...

Element creation in the lab deepens understanding of surface explosions on neutron stars

Element creation in the lab deepens understanding of surface explosions on neutron stars
2023-05-23
Led by Kelly Chipps of the Department of Energy’s Oak Ridge National Laboratory, scientists working in the lab have produced a signature nuclear reaction that occurs on the surface of a neutron star gobbling mass from a companion star. Their achievement improves understanding of stellar processes generating diverse nuclear isotopes. “Neutron stars are really fascinating from the points of view of both nuclear physics and astrophysics,” said ORNL nuclear astrophysicist Kelly Chipps, who led a study published in Physical Review Letters. “A deeper understanding of their dynamics may help reveal the cosmic ...

New treatment helps people stop addictive opioid painkillers used for chronic pain

2023-05-23
Programme of combined one-to-one and group support sessions was tested in landmark clinical trial After one year, one in five people were able to stop taking opioids without their pain increasing Experts say the new treatment is an alternative to opioid use and has potential to give patients better quality of life Researchers at the University of Warwick and The James Cook University Hospital, Middlesbrough have led a clinical trial, funded by the National Institute for Health and Care Research (NIHR), on a new treatment which can help people stop needing to use opioid painkillers to manage chronic pain. There are over 1 ...

CT scan best at predicting heart disease risk in middle age

2023-05-23
CHICAGO ---CT scans are better at predicting a middle-aged person’s risk for a heart disease, such as a heart attack, than genetics, reports a new Northwestern Medicine study.  “Finding the best way to identify who is at risk for developing heart disease can help determine what needs to be done to lower their risk,” said lead study author Dr. Sadiya Khan, an assistant professor of medicine and preventive medicine at Northwestern University Feinberg School of Medicine and a Northwestern Medicine cardiologist. “This finding can help doctors and patients in managing risk for heart disease, which is the leading cause ...

Study: Transcatheter mitral valve repair safe, successful

Study: Transcatheter mitral valve repair safe, successful
2023-05-23
Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists. Their findings on the condition called degenerative mitral regurgitation were published today in the peer-reviewed Journal of the American Medical Association (JAMA), representing the largest study to date that examines outcomes for patients treated outside of a clinical trial with transcatheter edge-to-edge repair (TEER). “Treatment was successful in nearly nine out of every 10 patients in whom TEER was used to repair ...

LAST 30 PRESS RELEASES:

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

[Press-News.org] Trial aims to improve treatment for newborns with life-threatening sepsis
An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.